.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,322,502

« Back to Dashboard

Details for Patent: 5,322,502

Title: Membrane for electrotransport transdermal drug delivery
Abstract:A membrane capable of inhibiting agent release from a delivery system when no electrical current is flowing and yet provide minimal impedance to electrically-assisted agent delivery, useful both for incorporating into electrotransport agent delivery systems and for use in measuring agent release rates in in vitro testing.
Inventor(s): Theeuwes; Felix (Los Altos, CA), Gyory; J. Richard (Los Altos, CA), Haak; Ronald P. (Cupertino, CA)
Assignee: Alza Corporation (Palo Alto, CA)
Filing Date:Jan 13, 1993
Application Number:08/003,761
Claims:1. A device for administering a drug iontophoretically through a predetermined area of skin in a therapeutically effective regimen comprising:

(a) a first reservoir of said drug in a form susceptible to iontophoretic administration in communication with said area of skin;

(b) a skin permeability enhancer contained within said first reservoir;

(c) a first electrode in electrical communication with said first reservoir;

(d) a second reservoir containing a electrolyte in communication with the skin at a location separated from said area of skin;

(e) a second electrode in electrical communication with the second reservoir;

(f) means for creating an electric voltage difference between the first and second electrodes; and

(g) a rate controlling membrane interposed between said first reservoir and said area of skin, said membrane being substantially impermeable to the drug when the voltage difference is absent and permeable to the drug when the voltage difference is present.

2. The device of claim 1, wherein the second reservoir contains a drug in a form susceptible to iontophoretic administration.

3. The device of claim 1, wherein the second reservoir contains a skin permeability enhancer.

4. The device of claim 2, wherein a second rate controlling membrane is interposed between the second reservoir and the skin.

5. The device of claim 1, wherein at least one of the first and second electrodes is comprised of silver.

6. The device of claim 1, including means for controlling the magnitude of electrical current applied by the voltage difference.

7. The device of claim 6, wherein the means for controlling controls the magnitude of electrical current to a substantially constant level.

8. The device of claim 1, including means for controlling the duration over which the electrical voltage difference is applied.

9. The device of claim 1, including means for reversing the polarity of the voltage difference.

10. The device of claim 1, wherein at least one of the first and second reservoirs comprises a solution of said drug.

11. The device of claim 1, where at least one of the first and second reservoirs comprises a gel.

12. A method of administering a drug iontophoretically through a predetermined area of the skin of a patient comprising:

placing a first reservoir comprising the drug in communication with said area of skin, said first reservoir having a first electrode in electrical communication therewith;

placing a second reservoir containing an electrolyte in communication with the skin at a location separated from said area, said second reservoir having a second electrode in electrical communication therewith; and

creating a voltage difference between the first and second electrodes, wherein a skin permeability enhancer is applied to said area of skin to make the skin substantially permeable to the drug and a rate controlling membrane is interposed between the reservoir and the area of skin, the membrane being substantially impermeable to the dug in the absence of the voltage difference and permeable to the drug in the presence of the voltage difference.

13. The method of claim 12, wherein at least one of the first and second reservoirs comprises a solution of the drug.

14. The method of claim 12, wherein at least one of the first and second reservoirs comprises a gel.

15. The method of claim 12, including controlling the magnitude of electrical current applied by the voltage difference.

16. The method of claim 12, including controlling the duration of electrical current applied by the voltage difference.

17. The method of claim 12, including reversing the polarity of the voltage difference.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc